Oncolys BioPharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.5%.

Top 18 shareholders own 23.64% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
4.27%	Rakuten Investment Management, Inc.	890,600	JP¥632.3m	39.2%	0.13%
3.48%	Astellas Pharma Inc.	727,200	JP¥516.3m	0%	no data
3.34%	Central Tanshi Co., Ltd., Asset Management Arm	696,200	JP¥494.3m	0%	1.89%
2.64%	SBI Holdings Inc., Asset Management Arm	551,114	JP¥391.3m	12.4%	0.14%
2.39%	Yasuo Urata	498,900	JP¥354.2m	0%	no data
2.19%	Roche Holding AG	456,600	JP¥324.2m	0%	no data
1.05%	Hitoshi Nakanishi	219,000	JP¥155.5m	5.8%	no data
0.98%	Japan Securities Finance Co. Ltd., Asset Management Arm	205,400	JP¥145.8m	64.1%	0.02%
0.62%	Taizo Kawabata	128,700	JP¥91.4m	0%	no data
0.57%	Asahi Intecc Co., Ltd.	118,600	JP¥84.2m	0%	no data
0.55%	Yasunari Kashihara	115,000	JP¥81.6m	0%	no data
0.51%	Monex Group, Inc., Asset Management Arm	106,188	JP¥75.4m	0%	1.26%
0.48%	au Kabucom Securities Co., Ltd., Asset Management Arm	100,500	JP¥71.4m	0%	0.29%
0.48%	Matsui Securities Co. Ltd., Asset Management Arm	100,000	JP¥71.0m	0%	0.32%
0.086%	Keiji Yoshimura	18,000	JP¥12.8m	0%	no data
0.0057%	Sumitomo Mitsui Financial Group Inc., Asset Management Arm	1,200	JP¥852.1k	-99.3%	no data
0.0048%	Shiro Ohki	1,000	JP¥709.9k	0%	no data
0.0029%	Katsufusa Tachiya	600	JP¥425.3k	50%	no data